IL28A抗体 新品

+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    

  
  

•  

   

     Western blot analysis using IL28A mouse mAb against SK-Br-3 (1) cell lysate.    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human brain tissues using IL28A mouse mAb with DAB staining.    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human esophageal cancer tissues using IL28A mouse mAb with DAB staining.    

  
  

The IL28A antibody is designed to detect interleukin-28A (IL-28A), a cytokine belonging to the type III interferon (IFN) family, also known as interferon lambda 2 (IFN-λ2). IL-28A is encoded by the *IL28A* gene and shares structural homology with IL-28B (IFN-λ3) and IL-29 (IFN-λ1). These cytokines bind to a heterodimeric receptor complex (IL-28R1/IL-10R2) to activate JAK-STAT signaling pathways, triggering antiviral and immunomodulatory responses. Unlike type I IFNs, type III IFNs primarily act on epithelial and mucosal surfaces, offering tissue-specific antiviral defense with reduced systemic inflammation.

IL28A antibodies are critical tools in research for detecting endogenous IL-28A expression in cells and tissues, enabling studies on its role in viral infections (e.g., hepatitis C, influenza, COVID-19), autoimmune disorders, and cancer. They are utilized in techniques like Western blotting, ELISA, and immunohistochemistry to quantify protein levels or visualize spatial distribution. Additionally, these antibodies aid in exploring IL-28A’s therapeutic potential, as recombinant IL-28A has shown promise in preclinical models for enhancing antiviral immunity or suppressing tumor growth. However, cross-reactivity with related IFN-λ isoforms requires careful validation to ensure specificity. Research on IL28A antibodies continues to advance understanding of type III IFN biology and their clinical applications.